--------------------------------------------------------------------------------

EXHIBIT 10.18

Amendment to Amended and Restated Agreement Between Genentech, Inc.
and F. Hoffmann-La Roche Ltd Regarding Commercialization of Genentech's
Products Outside the United States

 

            This Amendment to Amended and Restated Agreement Between Genentech,
Inc. and F. Hoffmann-La Roche Ltd Regarding Commercialization of Genentech's
Products Outside the United States (hereinafter, "Amendment") is made, effective
as of March 10, 2000 ("Amendment Effective Date"), by and among F. Hoffmann-La
Roche Ltd, Grenzacherstrasse 124, CH 4070 Basel, Switzerland ("ROCHE"),
Genentech, Inc., 1 DNA Way, South San Francisco, California USA 94080, Genentech
Europe Limited, Reid House, 31 Church Street, Hamilton, Bermuda HM FXV and
Genentech Biopharmaceuticals Limited, Reid House, 31 Church Street, Hamilton,
Bermuda HM FXV ("GENENTECH").

WHEREAS, ROCHE and GENENTECH have entered into that certain Amended and Restated
Agreement Between Genentech, Inc. and F. Hoffmann-La Roche Ltd Regarding
Commercialization of Genentech's Products Outside the United States
(hereinafter, the "Commercialization Agreement").

WHEREAS, ROCHE now wishes to not commercialize and market in Canada GENENTECH's
interferon gamma, Actimmune and to amend the Commercialization Agreement with
respect to this.

NOW, THEREFORE, THE PARTIES HERETO HEREBY AGREE AS FOLLOWS:

 1. All capitalized terms in this Amendment shall have the meanings given in the
    Commercialization Agreement unless otherwise expressly defined herein.
     
 2. Article 1, Section 5 of the Commercialization Agreement is hereby amended to
    delete Actimmune interferon gamma from the definition of "Canada Products."
     
 3. Except as expressly amended herein above, all of the terms and conditions of
    the Commercialization Agreement shall remain in full force and effect.

 

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by
their duly authorized representative as of the Amendment Effective Date.

 

GENENTECH, INC.

 

HOFFMANN-LA ROCHE LTD

         

By:

/s/ STEPHEN G. JUELSGAARD

 

By:

/s/ STEFAN ARNOLD

         

Name:

Stephan G. Juelsgaard

 

Name:

Stefan Arnold

         

Title:

Senior Vice President and General Counsel

 

Title:

Vice Director

                         

By:

/s/ R. SCHAFFNER

               

Name:

R. Schaffner

               

Title:

MP Director

                             

GENENTECH EUROPE LIMITED

             

By:

/s/ LOUIS J. LAVIGNE, JR.

     

         

Name:

Louis J. Lavigne, Jr.

     

         

Title:

Vice President and Chief Financial Officer

     

                   

GENENTECH BIOPHARMACEUTICALS LIMITED

             

By:

/s/ LOUIS J. LAVIGNE, JR.

     

         

Name:

Louis J. Lavigne, Jr.

     

         

Title:

Vice President and Chief Financial Officer

     

 

--------------------------------------------------------------------------------